Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Filament Health Corp (FLHLF)

Filament Health Corp (FLHLF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications ACCESSWIRE - Thu Dec 19, 3:00AM CST

Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications

FLHLF : 0.0263 (-14.61%)
FH : 1.52 (+9.35%)
JAGX : 0.9255 (+6.00%)
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications ACCESSWIRE - Thu Dec 19, 3:00AM CST

Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications

FLHLF : 0.0263 (-14.61%)
FH : 1.52 (+9.35%)
JAGX : 0.9255 (+6.00%)
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES Newswire.ca - Mon Dec 16, 6:00AM CST

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or "Filament Health"), a clinical-stage natural psychedelic drug development...

FLHLF : 0.0263 (-14.61%)
JAGX : 0.9255 (+6.00%)
FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Newswire.ca - Thu Nov 14, 6:14PM CST

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development...

FLHLF : 0.0263 (-14.61%)
FH : 1.52 (+9.35%)
FILAMENT HEALTH ANNOUNCES ISSUANCE OF COMMON SHARES TO NEGEV CAPITAL INVESTMENTS LIMITED PURSUANT TO ADVISORY AGREEMENT Newswire.ca - Fri Oct 4, 3:30PM CDT

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development...

FLHLF : 0.0263 (-14.61%)
FH : 1.52 (+9.35%)
FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Newswire.ca - Wed Aug 14, 4:32PM CDT

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development...

FLHLF : 0.0263 (-14.61%)
FH : 1.52 (+9.35%)
FILAMENT HEALTH ANNOUNCES MAJOR INTELLECTUAL PROPERTY EXPANSION Newswire.ca - Tue Aug 13, 6:00AM CDT

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development...

FLHLF : 0.0263 (-14.61%)
Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp. Newsfile - Fri Jun 14, 9:10PM CDT

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the "Acquiror"), a shareholder of Filament Health Corp. ("Filament"), announces that on June 12, 2024, it was...

FLHLF : 0.0263 (-14.61%)
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Newswire.ca - Wed Jun 12, 4:40PM CDT

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development...

COF : 178.65 (+1.70%)
FLHLF : 0.0263 (-14.61%)
FH : 1.52 (+9.35%)
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Newswire.ca - Mon Jun 3, 6:15AM CDT

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development...

FLHLF : 0.0263 (-14.61%)
FH : 1.52 (+9.35%)

Barchart Exclusives

How To Profit From The Latest Corporate Spinoffs: A Guide For Investors In 2025 Barchart - 47 minutes ago
How to navigate corporate spinoffs. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot